180 Life Sciences Corp. (ATNF): Price and Financial Metrics


180 Life Sciences Corp. (ATNF): $1.37

0.05 (+3.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATNF to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ATNF Stock Price Chart Interactive Chart >

Price chart for ATNF

ATNF Price/Volume Stats

Current price $1.37 52-week high $11.75
Prev. close $1.32 52-week low $1.00
Day low $1.26 Volume 147,000
Day high $1.37 Avg. volume 391,954
50-day MA $1.87 Dividend yield N/A
200-day MA $3.78 Market Cap 46.70M

180 Life Sciences Corp. (ATNF) Company Bio


180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.


ATNF Latest News Stream


Event/Time News Detail
Loading, please wait...

ATNF Latest Social Stream


Loading social stream, please wait...

View Full ATNF Social Stream

Latest ATNF News From Around the Web

Below are the latest news stories about 180 Life Sciences Corp that investors may wish to consider to help them evaluate ATNF as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

If you're looking for the biggest pre-market stock movers for Monday, we've got you covered with a list of gainers and losers for today.

William White on InvestorPlace | April 4, 2022

180 Life Sciences Corp. Forms Scientific Advisory Board

PALO ALTO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the formation of a scientific advisory board (SAB). Dr. Jonathan Rothbard, 180 Life Sciences Chief Scientific Officer stated, “We are pleased to announce the formation of the scientific advisory board

Yahoo | February 17, 2022

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

PALO ALTO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released the following letter to shareholders from its Chief Executive Officer, Dr. James Woody. Dear Fellow Shareholders, As you may recall, I previously authored a letter to you at the end of August 2021. I con

Yahoo | January 31, 2022

180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022

PALO ALTO, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that the Company will participate in the Biotech Showcase 2022 Virtual Conference to be held January 10-12, 2022. Dr. James Woody, President & Chief Executive Officer, will present an overview of 180 L

Yahoo | December 28, 2021

180 Life Sciences Corp. (NASDAQ:ATNF) COO Quan Anh Vu Buys 8,000 Shares

180 Life Sciences Corp. (NASDAQ:ATNF) COO Quan Anh Vu acquired 8,000 shares of the companys stock in a transaction dated Thursday, December 16th. The shares were bought at an average cost of $3.98 per share, with a total value of $31,840.00. The acquisition was disclosed in a document filed with the SEC, which is accessible []

Transcript Daily | December 16, 2021

Read More 'ATNF' Stories Here

ATNF Price Returns

1-mo -20.81%
3-mo -56.92%
6-mo -76.01%
1-year -83.96%
3-year N/A
5-year N/A
YTD -64.87%
2021 42.86%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5485 seconds.